Legend Biotech Corporation

NASDAQ:LEGN

Biotechnology

Healthcare
$16.25 -13.51%

-$4.53 today

Market cap
$3.01B
Beta
0.35
P/E (TTM)
-21.4
EPS (TTM)
-$1.35
52W Low $16.24High $45.30

Volume 2.15M

Average 2.42M

LEGN Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Legend Biotech CorporationNASDAQ: LEGN

Accounts Payables · Q3 FY2026 · quarter ended Sep 2026

Accounts payables turns negative

Q3 FY2026 accounts payables was -$5.2M, compared with $24.27M a year earlier. Trailing-twelve-month accounts payables was -$26.31M. Over 3 fiscal years it compounded at -15.0% a year.

Context

  • Accounts payables amounted to 4.3% of revenue in FY2025, up 2.1 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts payables holds near -$5.2M or moves back toward the trailing-twelve-month quarterly average of -$6.58M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$5.2M-278.5% QoQ
Last fiscal yearDec 2025
$44.52M+216.6% YoY
LTMSep 2026
-$26.31M-138.8% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-121.4%——
1 year+216.6%——
3-year CAGR-15.0%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
44.52M USD
Year-over-year change
+216.6%
4-year CAGR
+122.9%

Accounts Payables vs competitors

How LEGN compares with its peers on the latest reported figures

  • LEGN's LTM Sep 2026 accounts payables of $26.31M is the largest of the 11 companies compared; the peer median is $433.5K.
  • Its year-over-year change of -138.8% is the 8th highest of 11, against a peer median of -72.1%.
  • Accounts payables amounts to 1.9% of revenue for LEGN, versus a peer median of 3.3%.
LEGN Competitors Peer median
Accounts Payables for LEGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$26.31M -138.8%-15.0%1.9%
FATEFate Therapeutics, Inc.LTM Mar 2026$5.77M -408.6%—91.4%
AUTLAutolus Therapeutics plcLTM Mar 2026$1.74M -181.3%+289.5%1.9%
LYELLyell Immunopharma, Inc.LTM Mar 2026$1.7M +135.6%—5477.4%
CLLSCellectis S.A.LTM Mar 2026$1.34M -181.1%—2.0%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$747K -49.2%-22.8%3.2%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$443K -6.7%+126.3%25.0%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$424K -76.4%——
CRBUCaribou Biosciences, Inc.LTM Mar 2026$370K -77.8%—3.3%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$232K -67.8%——
DTILPrecision BioSciences, Inc.LTM Mar 2026$17K +117.0%—0.0%
Peer median (excluding LEGN) $433.5K-72.1%+126.3%3.3%

Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(407.2M)(445.72M)(520.12M)(158.13M)(297.58M)
Depreciation & Amortization13.92M18.39M20.45M23.36M28.9M
Deferred Income Tax00000
Stock-Based Compensation20.16M34.34M47.68M68.94M0
Change in Working Capital161.83M181.03M(71.34M)20.04M(93.35M)
Accounts Receivables24.59M50.32M(98.98M)93.75M(132.85M)
Inventory51K(13.89M)(12.71M)(17.21M)(4.51M)
Accounts Payables1.81M72.45M(50.2M)14.06M44.52M
Other Working Capital135.39M72.16M90.54M(70.57M)(501.32K)
Other Non-Cash Items12.82M10.68M130.06M(98.24M)261.57M
Operating Cash Flow(198.47M)(201.28M)(393.28M)(144.03M)(100.47M)
Capital Expenditures(45.4M)(22.28M)(22.72M)(14.11M)(67.58M)
Acquisitions (Net)00000
Purchases of Investments(377.96M)(654.97M)(4.86B)(2.71B)(4.55B)
Sales of Investments230.08M614.86M5.08B1.93B5.33B
Other Investing Activities(4.91M)(16.05M)(100.52M)(54.34M)0
Investing Cash Flow(194.98M)(77.09M)92.79M(850.54M)711.48M
Debt Repayment(1.42M)(2.6M)(3.76M)(4.02M)0
Common Stock Issued623.44M377.64M003.31M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities4.64M2.93M795.25M9.72M(3.61M)
Financing Cash Flow626.66M377.98M791.49M5.7M(300.79K)
Effect of Forex Changes34K(2.51M)682K(2.09M)4.37M
Net Change in Cash233.25M97.09M491.68M(990.96M)615.09M
Free Cash Flow(243.87M)(223.56M)(416M)(158.14M)(168.04M)

Legend Biotech Corporation

NASDAQ:LEGN

Intrinsic Alpha fair value

Locked

Current Price

$16.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.